News & Press

Corden Connect Shares Streamlined Growth in 2018

Edition 1 / March 2019
Editorial > An Operations Year in Review: Streamlined Product Improvement for Healthy Growth

Edition 1 / March 2018

CordenPharma’s Dr. Walter Kittl Chief Operating Officer, headshot

Dr. Walter Kittl

Chief Operating Officer,

An Operations Year in Review: Streamlined Product Improvement for Healthy Growth

Welcome to our Q1 2019 Edition 3 of Corden Connect – we hope you’ve had a successful start to the year! Since coming on board as Chief Operating Officer of CordenPharma in February 2018, I have worked together with the Leadership Team to create a Global Operations desk and put in place a top-down, bottom-up assessment of our facilities focused on four areas: project / product execution & management, superior operational & technical expertise, continuous improvement of quality, and lastly, cost control. This resulted in a successful streamlining of operations to implement product portfolio changes designed to meet the evolving demands of our customers.

Today we are pleased to have successfully replaced the legacy business inherited through the acquisition of our manufacturing assets from Big Pharma with a broad range of new capabilities. In this context, it is noteworthy that CordenPharma was able to demonstrate strong top line growth through the development of new accounts, representing customers spanning a wide range from small biotechs to mid-size and large pharma. In this process we expanded services to not only cover initial clinical phase I to commercial supply of APIs & Drug Products, but also formed a Fully-Integrated Supply solution which has been in strong demand and well-received by the market. So overall, while we initially started with a small customer base comprised mostly of legacy customers, we are now serving a broad and comprehensive customer base in key markets such as North America, Europe, Japan and India, which transformed our initial ~80% dependency on legacy business into a healthy outlook of 35%. All this requires world-class operations to meet your certain expectations regarding quality, cost, and a reliable supply chain.

We hope you enjoy reading Edition 3, where Platform Directors discuss our new Small Molecule Centre of Excellence and review the Oncology industry, and our Director of North America & Emerging Markets addresses supply chain management dynamics from a CDMO perspective.

As with the previous edition, we will continue to provide you with thought leadership, industry perspectives, and regular updates on recent developments in relation to our five Technology Platforms, which were created to provide you with the full benefit and added value of an Integrated Supply spanning early-phase to commercial manufacturing of APIs, Drug Products, and Pharma Packaging & Logistics. As a CDMO, delivering added-value to our customers remains our primary focus. To that end we continually strive towards transparent communication from corporate management to facility operators, all in support of our common goal to deliver critical medications to patients!

This Spring we look forward to a full schedule of engaging trade shows starting with DCAT Week ’19, an injectable presentation at PDA Europe, CPhI Japan, 2nd APV Conference on Highly Potent Drug Products and the APV 3rd European Conference on Pharmaceutics in March, followed by CPhI North America in April. Visit our events page for more information.

Stay Connected! Feel free to reach out directly to our Global Platform Directors or Key Account Managers with any questions or feedback on how we can add further value to your ideas, processes and projects by providing first-class service across our network.

Dr. Walter Kittl
COO, CordenPharma

Subscribe to our Newsletter

Stay up to date with the latest thought leadership articles and news from CordenPharma.